Advanced

Two-year outcome of Galantamine treatment in Alzheimer’s disease in a routine clinical setting.

Wallin, Åsa LU ; Wattmo, Carina LU ; Björkman, Annacarin; Eriksson, Sture; Andreasen, Niels and Minthon, Lennart LU (2006) 9th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy
Abstract
Objectives: To describe and evaluate the two-year outcome on cognition (MMSE, ADAS-cog) and global rating (CIBIC) of galantamine treatment in Alzheimer’s disease (AD) in a routine clinical setting. Methods: The Swedish Alzheimer Treatment Study (SATS) is an open, longitudinal, multicenter study evaluating cholinesterase inhibitor (ChEI) treatment in AD. Patients are investigated at baseline, at 2 months and every 6 months for a total period of three years. Here we present the two-year outcome for the first 123 patients receiving the ChEI galantamine in SATS. Results: At baseline the mean (±SD) age of the patients was 72.3 (±7.7) years, the MMSE score 23.3 (±4.2) and the ADAS-cog score 17.2 (±8.4). After two years of treatment the total... (More)
Objectives: To describe and evaluate the two-year outcome on cognition (MMSE, ADAS-cog) and global rating (CIBIC) of galantamine treatment in Alzheimer’s disease (AD) in a routine clinical setting. Methods: The Swedish Alzheimer Treatment Study (SATS) is an open, longitudinal, multicenter study evaluating cholinesterase inhibitor (ChEI) treatment in AD. Patients are investigated at baseline, at 2 months and every 6 months for a total period of three years. Here we present the two-year outcome for the first 123 patients receiving the ChEI galantamine in SATS. Results: At baseline the mean (±SD) age of the patients was 72.3 (±7.7) years, the MMSE score 23.3 (±4.2) and the ADAS-cog score 17.2 (±8.4). After two years of treatment the total mean decline from baseline in MMSE-score was 1.6 points (95% CI, 0.6 - 2.6). The ADAS-cog rise after two years was 3.8 points (95% CI, 1.9 - 5.6) i.e. significantly better than the score predicted by the Stern equation (8.3 points, 95% CI, 7.3 - 9.4). Half of the patients were considered unchanged or better in the CIBIC-rating after two years of treatment. At this time 70 % of the patients remained in the study. Conclusions: Long-term galantamine treatment in a routine clinical setting resulted in a positive effect in cognitive tests compared to historical controls and mathematical models. After 2 years of treatment a positive global outcome was observed in half of the patients. Dropout was less than expected. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to conference
publication status
published
subject
conference name
9th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy
language
English
LU publication?
yes
id
0eba18fa-730c-4849-ad00-1d69a32ee6ca (old id 2064212)
date added to LUP
2011-11-16 13:42:37
date last changed
2017-07-31 14:57:06
@misc{0eba18fa-730c-4849-ad00-1d69a32ee6ca,
  abstract     = {Objectives: To describe and evaluate the two-year outcome on cognition (MMSE, ADAS-cog) and global rating (CIBIC) of galantamine treatment in Alzheimer’s disease (AD) in a routine clinical setting. Methods: The Swedish Alzheimer Treatment Study (SATS) is an open, longitudinal, multicenter study evaluating cholinesterase inhibitor (ChEI) treatment in AD. Patients are investigated at baseline, at 2 months and every 6 months for a total period of three years. Here we present the two-year outcome for the first 123 patients receiving the ChEI galantamine in SATS. Results: At baseline the mean (±SD) age of the patients was 72.3 (±7.7) years, the MMSE score 23.3 (±4.2) and the ADAS-cog score 17.2 (±8.4). After two years of treatment the total mean decline from baseline in MMSE-score was 1.6 points (95% CI, 0.6 - 2.6). The ADAS-cog rise after two years was 3.8 points (95% CI, 1.9 - 5.6) i.e. significantly better than the score predicted by the Stern equation (8.3 points, 95% CI, 7.3 - 9.4). Half of the patients were considered unchanged or better in the CIBIC-rating after two years of treatment. At this time 70 % of the patients remained in the study. Conclusions: Long-term galantamine treatment in a routine clinical setting resulted in a positive effect in cognitive tests compared to historical controls and mathematical models. After 2 years of treatment a positive global outcome was observed in half of the patients. Dropout was less than expected.},
  author       = {Wallin, Åsa and Wattmo, Carina and Björkman, Annacarin and Eriksson, Sture and Andreasen, Niels and Minthon, Lennart},
  language     = {eng},
  title        = {Two-year outcome of Galantamine treatment in Alzheimer’s disease in a routine clinical setting.},
  year         = {2006},
}